Application (24A720) granted by Justice Alito extending the time to file until March 19, 2025. Motion to extend the time to ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase ...

Janux Therapeutics, Inc.’s JANX share price has dipped by 5.83%, which has investors questioning if this is right time to buy.

Dengue’s rise in 2024, influenced by climate change and shifting serotypes, underscores the need for effective vaccines to ...

Gilead Sciences (GILD) announced topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda ...

After an early wobble, markets resumed rising after Chinese officials contradicted suggestions from President Trump and ...

It has collaboration agreements with companies like Arcus Biosciences Inc. and Merck Sharp & Dohme Corp. It also has several other research collaborations, options, and license agreements.

C4 Therapeutics, Inc.’s CCCC share price has surged by 17.60%, which has investors questioning if this is right time to sell.

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC ...

Shares of Summit Therapeutics (NASDAQ:SMMT) ended five straight sessions of gains on Friday as the stock lost ~35%, ...

The European Commission has approved Merck Sharp & Dohme’s hepatitis C treatment Zepatier, creating new competition for Gilead and AbbVie’s established combination treatments. This puts it ...